0·38; 95% CI 0·22-0·63; p=0·0003] and OS [HR 0·35; 95% CI 0·15-0·70; p=0·005] for women with pCR compared to those without pCR. Women treated with the combination of lapatinib plus trastuzumab had better EFS with pCR than without pCR [HR 0·32; 95% CI 0·12-0·74; p=0·012]. Adverse events were consistent with known safety profile of lapatinib and/or trastuzumab.
Interpretation:
The observed correlation between pCR and improved EFS with dual HER2 blockade has implications for clinical care and reinforces the validity of neoadjuvant HER2 therapies while setting the stage for studies aimed at improving the outcome for patients that do not achieve a pCR.
Funding: GlaxoSmithKline

Introduction:
Overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) occurs in approximately 15% of breast cancers and is associated with poor prognosis (1). Anti-HER2 drugs such as trastuzumab (monoclonal antibody; Herceptin, Genentech, California, CA, USA) and lapatinib (tyrosine kinase inhibitor; Tykerb, GlaxoSmithKline, Brentford, UK) are widely used for the treatment of HER2-positive breast cancer, with the former being approved for use in the metastatic and adjuvant settings while the latter for the metastatic setting only (2) (3) (4) (5) (6) . A previous report of the NeoAdjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) phase III, randomized trial showed that dual anti-HER2 blockade with lapatinib and trastuzumab combined with weekly paclitaxel significantly increased the rate of pathological complete response (pCR) compared to trastuzumab and weekly paclitaxel (51·3% vs. 29·5% respectively; p= 0·0001) (7) . In a recent meta-analysis funded by the US Food and Drug Administration (FDA) involving 11·955 patients, reaching pCR after neoadjuvant therapy was significantly associated with better event-free survival (EFS) and overall survival (OS), particularly in the HER2-positive population (N= 1·989) irrespective of hormone receptor status (Hazard Ratio (HR) 0·39 for EFS and HR 0·34 for OS) (8) .
As previously reported, the primary objective was to compare the rate of pCR as defined by the NSABP guidelines (absence of residual invasive disease in the breast) (7) . Secondary objectives pre-specified in the NeoALTTO protocol were to evaluate the effect of treatment on EFS and OS as well as the association between achieving locoregional pCR (ypT0/is ypN0) and survival outcomes. We report results at a median follow up of 3·77 years in 455 women with HER2-positive EBC enrolled in the NeoALTTO trial.
Methods
Study design and patients:
The NeoALTTO trial (Breast International Group 1-06) was previously reported in detail (7) . In summary, 455 women were randomised between January 5, Left ventricular ejection fraction (LVEF) at baseline had to be 50% or more.
Women with bilateral, inflammatory or metastatic breast cancer were not eligible (7).
The ethics committee and relevant health authorities at each participating institution approved the study protocol. All participating women gave written informed consent prior to study entry.
Randomisation and masking:
This section was extensively reported in the first publication, which focused on the primary endpoint of pathological complete response (pCR) (7).
Procedures:
Neoadjuvant treatments and doses are summarized in Table 1 . Women received oral lapatinib, intravenous trastuzumab, or lapatinib plus trastuzumab for 6 weeks (biological window), followed by an additional 12 weeks of the assigned anti-HER2 therapy plus weekly paclitaxel. Definitive surgery was performed 4 weeks after the last dose of paclitaxel. Chemotherapy was given to all women within 6 weeks of definitive surgery and consisted of 3 cycles of FEC weeks to complete a total duration of 52 weeks (1 year) of anti-HER2 therapy.
Radiotherapy given concomitantly with anti-HER2 drugs was mandatory in 
Adjuvant phase
FEC 5-fluorouracil 500 mg/m² + epirubicin 100 mg/m² + cyclophosphamide 500 mg/m² given IV every 3 weeks for a total of 3 cycles Anti-HER2 drugs 1500 mg daily (orally) for 34 weeks 8 mg/kg loading dose followed by 6 mg/kg IV for 34 weeks (every 3 weeks) 1000 mg daily (orally) for 34 weeks + 8 mg/kg loading dose followed by 6 mg/kg IV for 34 weeks (every 3 weeks)
Abbreviations: IV: intravenous
Note: * An amendment was introduced to reduce the dose of lapatinib to 750 mg daily when paclitaxel was added in order to reduce the incidence of diarrhoea (amendment 2 October 2008); 54 of 152 women received treatment at reduced dose due to the fast accrual of the trial.
women treated with breast conserving surgery and was given according to local guidelines in case of mastectomy and started 4 weeks after completion of FEC. 
Outcomes
The primary endpoint was pCR which was reported in 2012 and was defined as the absence of invasive tumour cells in the breast at the time of surgery (7).
Secondary endpoints included locoregional pCR, disease-free and overall survival, safety and tolerability. An amendment released in May 2013 replaced disease-free survival with EFS to align with the FDA recommendations.
Accordingly, EFS was defined as the time from randomization to first EFS event.
For women who underwent breast cancer surgery, EFS events were defined as 
Statistical Analysis:
The trial was powered to detect differences between treatment groups with respect to pCR rate. Assessment of EFS and OS outcomes is therefore descriptive, and p-values are presented as measures of variability and not for inferential purposes. These were pre-planned analysis even if the number of expected events is low (10, 11) . Differences in EFS and OS between the trastuzumab group and each of the lapatinib-containing groups are described using hazard ratios and 95% confidence intervals with p-values from two-sided stratified log-rank tests, implemented as Wald tests from the Cox models (12).
Tests of proportionality were performed. All 455 patients (i.e. the ITT population)
were included in these analyses.
Associations between pCR and EFS/OS were examined using landmark analyses (13, 14) . pCR is a "categorizing" event known after study entry and therefore analyses of "outcome" events according to pCR are potentially subject to guarantee time bias (GTB). The landmark analysis controls for GTB. A 30-week landmark time was selected as it would be sufficiently long for primary breast cancer surgery to be performed and not too long to eliminate the occurrence of EFS events. Date of surgery is patient dependent and thus not as free of GTB as the landmark approach for analyses in this report designed to assess the EFS and OS outcomes comparing patients who did or did not achieve pCR,
For EFS/OS, the 30-week landmark population included only women who were still in clinical (survival) follow-up and were event-free (alive) at 30 weeks after randomization (web appendix 1A and 1B). Patients were allocated to two groups according to their pCR status recorded up to week 30 from randomization, and these groups were compared with respect to EFS/OS. Twosided stratified log-rank tests of EFS/OS were implemented as Wald tests from the Cox model (12) with pCR status and assigned treatment arm fitted as covariates and the stratification factors entered as strata variables (Web appendix 2). Of note, the number of patients with missing pCR status is low and so these patients were excluded from the landmark analysis.
Supplemental analyses were also performed where pCR status was included as a time dependent covariate in Cox proportional hazards models of EFS and OS from randomization in all women in the ITT population whose pCR status was known. These models were adjusted for the assigned treatment group, tumour size and other stratification variables.
All analyses of EFS and OS were repeated separately for the hormone receptor positive and negative cohorts. Differences in characteristics of these two cohorts were summarized using Fisher exact tests.
Incidence rates and exact 95% confidence intervals (15) were calculated for the primary cardiac endpoint and any cardiac endpoint for each treatment group separately. Incidence rates in the lapatinib-containing groups were compared with the incidence rates in the trastuzumab group using unstratified binomial pairwise comparisons.
Analyses were done with SAS (version 9·3)
This trial is registered with ClinicalTrials.gov, NCT00553358.
Role of the funding source:
GlaxoSmithKline, the manufacturer of lapatinib, distributed the study drugs and provided financial support to the trial, but imposed no restrictions on the investigators with respect to study design, data collection, data analysis, data interpretation, and writing of this manuscript. The corresponding author had full access to all data and had final responsibility for the decision to submit for publication.
The first manuscript draft was written by two authors (Evandro de Azambuja and José Baselga) and the study statisticians (Andrew P. Holmes and Eileen Holmes). All authors reviewed and approved the manuscript prior to submission.
Results:
Figures 1A and 1B show the trial profile. As previously reported, 154 women were assigned to the lapatinib group, 149 to the trastuzumab group and 152 to geographical location and medical history were described elsewhere (7). This report presents a pre-specified analysis at 3 years after the last woman had breast cancer surgery. The median clinical follow-up is 3·77 years (95% CI 3·72-3·98) and the median survival follow-up is 3·84 years (95% CI 3·77-3·98) from randomisation. For these analyses, stratification factors (hormone receptor status, clinical tumour size, clinical status of lymph nodes and planned breast conserving surgery) were well balanced across the three treatment groups in the intention-to-treat (ITT) population (Web appendix 2).
Adverse events were assessed in 448 women who received at least one study drug dose. Generally, more adverse events (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0) occurred in both groups receiving lapatinib compared to the trastuzumab alone group (Table 2) . Of note, the protocol applied strict definitions for hepatic adverse events, which were only applicable to the lapatinib-containing arms, leading to permanent lapatinib discontinuation and reporting of serious adverse events. There was a higher incidence of neutropenia adverse event in the lapatinib-containing groups without increase in febrile neutropenia (excluding FEC administration period). The incidence of primary cardiac events remained very low in all three treatment groups (0·67% overall). The incidence of any cardiac events was higher in the lapatinib plus trastuzumab group compared to either lapatinib or trastuzumab groups (4·70% vs. 1·32% vs. 1·35%, respectively) ( Table 2) . No fatal adverse event related to the study drugs was observed in this study. With 54 OS events, the 3-year OS was better in the lapatinib plus trastuzumab group compared to either lapatinib or trastuzumab alone for the whole Web appendix 3). Hazard ratios for OS were 0·62 (95% CI 0·30-1·25; p=0·19) for the lapatinib plus trastuzumab group and 0·86 (95% CI 0·45-1·63; p=0·65) for the lapatinib group compared to the trastuzumab group. Tests of proportionality of the hazards assumption showed no evidence of non-proportionality for the analysis of OS in the lapatinib plus trastuzumab group (p=0.39) and the lapatinib group (p=0.12) comparisons. These results should be interpreted with caution as the trial was not powered to detect significant differences in survival outcomes.
We considered the pCR status at the 30-week landmark for the 411 patients The landmark analysis of EFS included 137 women with pCR versus 274 women without pCR. Forty-four women were excluded from the landmark analysis: 6 with events prior to landmark, 24 with clinical follow-up ended prior to the landmark and 14 with missing pCR status. The 3-year EFS was significantly better for women with pCR compared to those without pCR (HR 0·38, 95% CI 0·22-0·63; p=0·0003) ( Figure 3A) . In pre-planned analyses, the hazard ratios for the hormone receptor negative cohort (HR 0·34, 95% CI 0·17-0·63; p=0·001; Figure 3D ). In pre-planned analyses, the hazard ratios for the hormone receptor negative cohort (HR 0·29, 95% CI 0·11-0·62; p=0·003; Figure 3E ) and the hormone receptor positive cohort (HR 0·85, 95% CI 0·13-3·42; p=0·84; Figure 3F) were not significantly different (interaction p=0.36).
The time-dependent Cox proportional models for EFS and OS showed similar results to those observed in the landmark analyses. The hazard ratios for the time-dependent covariate were 0·37 for EFS (95% CI 0·22-0·63; p=0·0002) and 0·34 for OS (95% CI 0·16-0·72; p=0·0046). This indicated that patients who achieved a pCR after neoadjuvant therapy had a reduced risk of subsequent EFS events and death compared with those who had not achieved pCR.
Discussion:
Although the NeoALTTO trial was not powered to detect significant differences in survival outcomes, the study results suggest that the combination of lapatinib plus trastuzumab prolongs EFS and OS [hazard ratio 0·78 (95% CI 0·47-1·28)
for EFS and 0·62 (95% CI 0·30-1·25) for OS]. It also confirms that women achieving pCR after neoadjuvant anti-HER2 therapies experience a significantly better EFS and OS [HR 0·38 (95% CI 0·22-0·63) and 0·35 (95% CI 0·15-0·70),
respectively]. We also demonstrated that women treated with lapatinib plus trastuzumab who reached pCR had a better 3-year EFS and a significant reduction in the risk of an EFS event (hazard ratio 0·32; 95% CI 0·12-0·74) compared to no pCR. Importantly, our trial is unique since all women received anti-HER2 therapy in the adjuvant phase that was the same as the anti-HER2 therapy randomly assigned for the neoadjuvant phase. Also, to our knowledge, this is the first trial to correlate pCR with survival outcomes in women treated with dual anti-HER2 drugs (lapatinib plus trastuzumab). Other trials have also shown that patients treated with neoadjuvant chemotherapy and trastuzumab and experiencing pCR have better survival outcomes compared to no pCR (16) (17) (18) . The NOAH trial showed that patients treated with neoadjuvant trastuzumab and experiencing pCR had a better EFS compared to those without pCR after a median follow-up of 5·4 years (hazard ratio 0·17; 95%CI 0·08-0·38; p<0·0001) (19) . In our trial, we demonstrated that pCR is correlated with better EFS and OS and that patients treated with the combination of lapatinib plus trastuzumab have the largest benefit of it, particularly in the hormone receptor negative cohort.
Importantly, our findings support the notion that HER2-positive hormone receptor positive and hormone receptor negative are two distinct diseases. In the landmark analysis, there was a significant difference in the hormone receptor negative cohort [EFS hazard ratio 0·34 (95% CI 0·17-0·63) and OS hazard ratio 0·29 (95% CI 0·11-0·63)] which was not present in the hormone receptor positive cohort. Our trial previously showed that patients with hormone receptor negative tumours experience more pCR than the hormone receptor positive cohort (7) . This was also demonstrated in other neoadjuvant trials testing the combination of lapatinib plus trastuzumab (20, 21) . Therefore, the authors do believe that new neoadjuvant trials should address these two patient populations separately. In the metastatic setting, the combination of both anti-HER2 drugs (without chemotherapy) showed a significantly better progression- Toxicity rates were higher in both lapatinib-containing groups although they were as expected (diarrhoea, rash or erythema, and hepatic toxicity). Also, more patients had to stop neoadjuvant treatment (21-22%) due to side effects in the lapatinib-containing groups (Table 3) . Importantly, no major cardiac concerns were raised particularly with the combination of both anti-HER2 drugs (any cardiac event, 4·7%). In case of adjuvant trastuzumab, there are some data showing the reversibility of trastuzumab-related cardiotoxicity at 8 years of median follow-up (24). Nevertheless, longer follow-up data on the combination of lapatinib plus trastuzumab is still lacking.
In an exploratory analysis in our trial, early rash (i.e., before starting paclitaxel)
was independently associated with a higher chance of pCR, mainly in patients older than 50 years (odds ratio [OR] = 3·76; 95% CI, 1·69-8·34), but not in those ≤ 50 years (OR = 0·92; 95% CI, 0·45-1·88; P for interaction = 0·01). No significant association was observed between pCR and diarrhoea or hepatic AEs (25). At this time, there are no tools available to identify the patients who will benefit the most from the combination of lapatinib plus trastuzumab in the neoadjuvant setting. The authors are also not able to identify a subgroup of patient that could discriminate those likely to experience adverse events at this moment.
A limitation of our study is that the sample size was powered to detect differences in pCR but not in EFS or OS; therefore all survival analyses are meant to be descriptive as mentioned. On the other hand, our trial has a unique feature which is using in the adjuvant setting the same assigned neoadjuvant anti-HER2 therapy. This was not that case for other neoadjuvant trials which have completed 1 year of adjuvant therapy with trastuzumab (standard of care).
In terms of pCR rates, one neoadjuvant trial testing dual HER2 blockade (pertuzumab plus trastuzumab) reported similar pCR rates compared to our trial while other trial reported a higher pCR rate (26, 27); However it is difficult to compare pCR rates across studies since the definitions used may be different and the type and duration of chemotherapy also varies. For example, in one of them, patients received all chemotherapy prior to surgery (27). In one study, Tryphaena, definition of pCR included breast only (ypT0/is) and did not take into account axillary lymph nodes (27). The NSABP B-41 trial also tested lapatinib plus trastuzumab in the neoadjuvant setting and found a non-significant increase in pCR rates with this combination compared to single HER2 agent (21) .
In summary, our results show that patients experiencing pCR after neoadjuvant anti-HER2 therapies have a better survival outcome compared to those without pCR. These findings support the neoadjuvant approach to test new drugs in EBC allowing rapid assessment of drug efficacy since pCR is a short-term outcome and the number of patients included in neodjuvant trials is not large. If this approach is proven to be optimal, this could expedite development and approval of new treatments in patients with HER2-positive EBC. However, more proof of this concept is desirable at this moment. A pre-planned protocol efficacy analysis will be performed in 2.5 years. We identified full text of two randomized study of patients treated with neoadjuvant lapatinib plus trastuzumab combined with chemotherapy and one combined with endocrine therapy (18, 19, 28) . The combination of lapatinib plus trastuzumab was also tested in an adjuvant trial recently presented (23) .
Interpretation:
Dual blockade with lapatinib plus trastuzumab combined with weekly paclitaxel increases pCR compared to either agent alone plus chemotherapy. Patients achieving pCR following neoadjuvant therapy have longer EFS and OS. Women treated with the combination of lapatinib plus trastuzumab and with pCR have a better 3-year EFS compared to those without pCR.
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